Beyond Air, Inc. (XAIR)
| Market Cap | 107.88M |
| Revenue (ttm) | 695,801 |
| Net Income (ttm) | -22.06M |
| Shares Out | 17.12M |
| EPS (ttm) | -1.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $6.22 |
| Previous Close | $6.50 |
| Change ($) | -0.28 |
| Change (%) | -4.31% |
| Day's Open | 6.44 |
| Day's Range | 6.13 - 6.50 |
| Day's Volume | 257,125 |
| 52-Week Range | 3.94 - 10.93 |
Call scheduled for Tuesday, February 9th at 4:30 pm Eastern Time Call scheduled for Tuesday, February 9th at 4:30 pm Eastern Time
Beyond Air Offers Compelling Value Heading Into Its First Potential Product Approval
GARDEN CITY, N.Y., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (...
Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q2 2021 Results - Earnings Call Transcript
Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating im proved economics and safety in hospital setting
Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time
Patients with pneumonia caused by any virus, including SARS-CoV-2, will be considered for enrollment
New in vivo data for colon cancer show anti-tumor immunity in 100% of mice
In vitro data support development of nitric oxide as a potential coronavirus therapy that acts within hours
150 ppm nitric oxide was statistically significant compared to both control and 85 ppm nitric oxide arms on the primary and key secondary endpoints
GARDEN CITY, N.Y., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (...
GARDEN CITY, N.Y., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxid...
GARDEN CITY, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxid...
GARDEN CITY, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide...
Heterogeneity in M. abscessus susceptibility to NO
Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q1 2021 Results - Earnings Call Transcript
AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Conference call at 8:30 a.m. ET Conference call at 8:30 a.m. ET
Shares of Beyond Air Inc (NASDAQ:XAIR) rose by 2.9% from the previous closing price.
Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q4 2020 Results - Earnings Call Transcript
Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints
Data demonstrate the ablation of solid tumors with nitric oxide
AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
GARDEN CITY, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide...
Anticipate study start in June 2020 Anticipate study start in June 2020
High concentration nitric oxide (150 ppm) is statistically significant compared to both low concentration nitric oxide (85 ppm) and control arms on both the primary endpoint and the key seco...
GARDEN CITY, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide ...
Term to run through May 2023
Food and Drug Administration (FDA) agrees to a trial using the LungFit ™ system to treat COVID-19 patients
Prepared to test LungFit™ BRO in COVID-19 patients in a clinical study starting in April pending FDA approval of recently submitted IDE (investigational device exemption) Prepared to test Lung...
Beyond Air Inc. XAIR, +17.05% said Monday that it submitted an investigational device exemption to the Food and Drug Administration (FDA) as it seeks authority to market its nitric oxide devic...
Beyond Air: Buy The Stock Ahead Of March 5 Analyst Day
Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q3 2020 Results - Earnings Call Transcript
AIT Therapeutics, Inc. (XAIR) delivered earnings and revenue surprises of -30.30% and -45.39%, respectively, for the quarter ended December 2019.
GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing ...
GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing ...
GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing ...
GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing ...
Exclusive five-year global agreement
About XAIR
Beyond Air, a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name t... [Read more...]
| Industry Medical Devices | |
| CEO Steven Lisi | Employees 23 |
| Stock Exchange NASDAQ | Ticker Symbol XAIR |
Financial Performance
In 2019, Beyond Air's revenue was $1.39 million, a decrease of -82.00% compared to the previous year's $7.72 million. Losses were -$19.94 million, 204.1% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Beyond Air stock is "Buy." The 12-month stock price forecast is 13.25, which is an increase of 113.02% from the latest price.